Axa’s Autolus Therapeutics AUTL Stock Holding History

Axa’s Portfolio AUTL Stock Details AUTL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-3,126,167	Closed	-$7.13M	–	155
2025 Q2	$7.13M	Hold	3,126,167	–	–	0.02%	480
2025 Q1	$4.85M	Buy	3,126,167 +1,301,482	+71%	+$2.64M	0.02%	549
2024 Q4	$4.29M	Buy	+1,824,685	New	+$6.17M	0.01%	579

Other funds holding AUTL

MCO

MAK Capital One New York $679M AUM 29.02% 1-Year Est. Return

Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return

Syncona Portfolio St Peter Port, Guernsey $25.7M AUM 13.32% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

TAM

TFG Asset Management Grand Cayman, Cayman Islands $515M AUM 24.47% 1-Year Est. Return

Schroder Investment Management Group London, United Kingdom $122B AUM 29.27% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Axa's AUTL Position: Q3 2025 in Review

Axa sold out of Autolus Therapeutics (AUTL) in Q3 2025, closing a stake of 3,126,167 shares — an estimated $7.13M sold.

Axa first reported a position in AUTL in Q4 2024 and held it in 3 quarters. The position peaked at $7.13M in Q2 2025. 96 funds tracked by Wall St. Rank hold AUTL as of Q3 2025.

Axa reported no remaining Autolus Therapeutics position as of Q3 2025 after selling out during the quarter.
Axa sold 3,126,167 Autolus Therapeutics shares in Q3 2025, an estimated $7.13M.
Axa first reported a position in Autolus Therapeutics in Q4 2024 and held it in 3 quarters.
Axa's Autolus Therapeutics position peaked at $7.13M in Q2 2025.
96 funds tracked by Wall St. Rank held Autolus Therapeutics as of Q3 2025.

Based on Axa's 13F filing for Q3 2025, filed 14 Nov 2025.